SCHEMBL23229282

SCHEMBL23229282

CCOc1ccccc1CC(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.50
MAPT P10636 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TSHR P16473 1/20 0.48
MTNR1A P48039 5/20 0.47
MTNR1B P49286 5/20 0.47
GLA P06280 1/20 0.46
TBXAS1 P24557 1/20 0.43
GLS O94925 1/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HTR7 P34969 1/20 0.43
GAA P10253 2/20 0.42
MEN1 O00255 1/20 0.42
THRB P10828 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
KMT2A Q03164 1/20 0.42
ATM Q13315 1/20 0.42
PLEC Q15149 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11051509 0.85 MTNR1A (0.50) L3MBTL1MTNR1AMTNR1BTDP1
SCHEMBL27365553 0.84 MTNR1A (0.59) L3MBTL1MAPTTSHRMTNR1AMTNR1B
SCHEMBL9863289 0.83 MTNR1A (0.52) L3MBTL1MTNR1AMTNR1BALDH1A1KDM4E
SCHEMBL7890168 0.82 TBXAS1 (0.59) L3MBTL1MAPTNPSR1TSHRGLA
SCHEMBL7847681 0.82 TSHR (0.58) L3MBTL1MAPTNPSR1TSHRGLA
SCHEMBL30104114 0.82 TSHR (0.58) L3MBTL1MAPTNPSR1TSHRGLA
SCHEMBL23478172 0.82 L3MBTL1 (0.70) L3MBTL1MAPTNPSR1TSHRGLA
SCHEMBL31274509 0.82 L3MBTL1 (0.70) L3MBTL1MAPTNPSR1TSHRGLA
SCHEMBL23241802 0.80 MTNR1A (0.46) L3MBTL1TSHRMTNR1AMTNR1BALDH1A1
SCHEMBL16410290 0.80 CFD (0.41) L3MBTL1MAPTMTNR1AMTNR1BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed